428 research outputs found
Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation
No full textCarnitine and its congeners may regulate the immune networks, and their influence on functions of immune cells predominantly or exclusively relies on carnitine-dependent energy production from fatty acids. A reduced pool of carnitines has been demonstrated in either serum or tissues, or both, from patients with a wide spectrum of disorders characterized by unregulated or impaired immune responses ranging from sepsis syndrome to systemic sclerosis, infection with human immunodeficiency virus, and chronic fatigue syndrome. Furthermore, experimental studies have consistently reported that the deranged immune responses and the less efficient inflammation towards infectious organisms associated with aging may be enhanced or modulated by treatment with carnitines. There is also evidence that carnitine deprivation could adversely affect the course of the sepsis syndrome, at least in experimental models, and preliminary studies suggest that carnitine deficiency is ultimately implicated in the pathophysiology of endotoxin-mediated multiple organ failure. Several data indicate that carnitine deficiency is a contributing factor to the progression of infection with human immunodeficiency virus, and carnitine therapy in those patients could counteract the unregulated process of lymphocyte apoptosis and improve CD4 counts. Some case reports have suggested the use of carnitine for the treatment of the severe lactic acidosis that complicates in some patients the use of reverse transcriptase inhibitor
Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial.
No full textRecurrent aphthous stomatitis is a common disorder of the oral cavity, affecting mainly young people. It is characterized by small ulcers which can be very painful and generally heal spontaneously within 7–14 days. There is currently no therapy that can provide rapid healing. This study evaluated the efficacy and rapidity of response of a lozenge containing Lactobacillus brevis CD2. 30 patients were randomized to take 4 lozenges a day of active product or placebo for 7 days. Signs and symptoms as well as laboratory parameters in the saliva were assessed at the start of the study and after 7 days of treatment. The study demonstrated the efficacy and the rapidity of response of the Lactobacillus brevis CD2 lozenges in resolving the clinical signs and symptoms of aphthous stomatitis, with a significantly rapid improvement of pain. This is the first study confirming the efficacy of a probiotic product in this pathology
Prefazione
No full textRiflessioni sul rapporto fra storiografia 'alta' e 'bassa' e del rapporto fra 'globale' e 'locale' in riferimento alla vicenda storico-artistica della chiesa dei SS. Sebastiano e Rocco in San Vito Romano (Roma)
The z > 3 AGN population in the 4 Ms CDFS
No full textWe present results from a spectral analysis of a sample of 34 high-redshift (z > 3) X-ray selected AGN in the 4 Ms Chandra Deep Field South, the deepest X-ray survey to date. The intrinsic column density distribution, corrected for observational bi- ases using spectral simulations, and the source number counts down to flux F0.5−2keV∼ 4 × 10−17 erg s−1 cm−2 are compared with the expectations from X-ray background synthesis models. All the results are presented and discussed in Vito et al. (2013)
Probiotic lactobacilli: A new perspective for the treatment of inflammatory bowel disease
No full textInflammatory bowel disease, such as ulcerative colitis and Crohn's disease, results from an interaction between susceptibility genes, the host's bacterial environment, gut barrier defects, and immunological factors. New management approaches have been evolved from advances in our understanding of the pathobiology of this common gut disorder In particular, the therapeutic manipulation of the bacterial microenvironment in the gut seems to offer an innovative tool for the treatment of those patients. Since the gut is a highly sensitizing organ that contributes to the systemic imune response, potent treatments need to be developed to reduce gut inflammation in this disorder. Recent studies have demonstrated that probiotic lactobacilli, and also immunostimulatory DNA sequences from those same bacteria have an important anti-inflammatory potential in this context. Future research should better define among patients with inflammatory bowel disease the various clinical phenotypes with the greatest potential of response to probiotic treatment. Identification of the genes leading to the disease and a rather better understanding of the underlying immunoregulatory abnormalities will be crucial steps to define the different profiles of interaction between endogenous digestive bacterial flora and the immune system in each individual patient. Such advances will probably lead to targeting of effective treatments, including bacteriotherapy with probiotic lactobacilli, to subsets of patients with inflammatory bowel disease
The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes
No full textBACKGROUND: The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient's quality of life. OBJECTIVES: To review currently available measures and investigational agents to prevent OM in hematological patients. METHODS: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. RESULTS/CONCLUSIONS: Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.Pasquale Niscola, Andrea Tendas, Luca Cupelli, Gianfranco Catalano, Laura Scaramucci, Marco Giovannini, Vito Trinchieri, Atul Sharma, Fabio Efficace, Claudio Cartoni, Daniela Piccioni, Alessio Perrotti, Teresa Dentamaro, Paolo de Fabritiis and Dorothy M.K. Keef
Vito Volterra
No full textVito Volterra (1860-1940) was one of the most famous representatives of Italian science in his day. Angelo Guerragio and Giovanni Paolini analyze Volterra’s most important contributions to mathematics and their applications, as well as his outstanding organizational achievements in scientific policy. Volterra was one of the founding fathers of functional analysis and the author of fundamental contributions in the field of integral equations, elasticity theory and population dynamics (Lotka-Volterra model). He delivered keynote lectures on the occasion of the International Congresses of Mathematicians held in Paris (1900), Rome (1908), Strasbourg (1920) and Bologna (1928). He became involved in the scientific development in united Italy and was appointed senator of the kingdom in 1905. One of his numerous non-mathematical activities was founding the National Research Council (Consiglio Nazionale delle Ricerche, CNR). During the First World War he was active in military research. After the war he took a clear stand against fascism, which was the starting point for his exclusion. In 1926 he resigned as president of the world famous Accademia Nazionale dei Lincei and was later on excluded from the academy. In 1931 he was one of the few university lecturers who denied to swear an oath of allegiance to the fascistic regime. In 1938 he suffered from the impact of the racial laws. The authors draw a comprehensive picture of Vito Volterra, both as a great mathematician and an organizer of science
Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing
No full textBackgroundVariability in probiotics manufacturing may affect their properties, with potential implications for their efficacy and safety. This is of particular concern with probiotic products destined for use in patients with serious medical conditions, including human immunodeficiency virus (HIV) infection. The purpose of the study was to carry out a series of experiments comparing the properties of the US-made probiotic formulation originally commercialized under the brand name VSL#3®, with those of the Italian-made formulation now commercialized under the same name. The US-made formulation has previously shown beneficial effects at the intestinal and neurological levels in HIV-infected subjects as well as in patients with inflammatory bowel diseases and hepatic encephalopathy.MethodsEleven subjects receiving combined antiretroviral therapy for HIV-1 were treated for 6 months with the US-made VSL#3 formulation. At baseline and 6 months, T-cells were analyzed for phenotype and activation markers, and fecal samples were analyzed for bifidobacteria, lactobacilli, and their metabolites. The fecal metabolome was assessed using 1H-NMR spectroscopy. Production of metabolites of interest by bacteria obtained from sachets of the two formulations was compared in vitro and their effects on a rat intestinal epithelial cell line (IEC-6) were assessed. Particular attention was paid to the metabolite 1,3-dihydroxyacetone (DHA).ResultsAt 6 months, fecal samples showed a significant increase in the specific bacterial genera contained in the probiotic supplement. Immune activation was reduced as shown by a significant reduction in the percentage of CD4+CD38+HLA-DR+ T-cells at 6 months. Fecal concentrations of DHA decreased significantly. In vitro, significant differences in the production and metabolism of DHA were found between bacteria from the US-made and Italian-made formulations: the US-made formulation was able to metabolize DHA whereas the bacteria in the Italian-made formulation were producing DHA. DHA reduced the viability of Streptococcus thermophilus, reduced IEC-6 cell viability in a dose-dependent manner, and also led to a lower rate of repair to scratched IEC-6 cell monolayer.ConclusionOur data, in conjunction with previously published findings, confirm that the new Italian-made formulation of VSL#3® is different from the previous US-made VSL#3 and therefore its efficacy and safety in HIV-infected subjects is still unproven
Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis
No full textThe purpose of this study was to determine the effectiveness of Lactobacillus-containing vaginal tablets in the treatment of bacterial vaginosis (BV) and in the restoration of a healthy vaginal flora. Thirty-nine women with BV were enrolled in a double-blind, placebo-controlled clinical trial. Patients received either one Lactobacillus-containing tablet or placebo daily for 7 days. Clinical criteria, vaginal Gram stain scores and symptoms were compared with those at the initial visit and those at completion of therapy and 2 weeks later. After completion of therapy, all of the patients in the Lactobacillus-treated group (n = 18) were free of BV, showing a normal (83%) or intermediate (17%) vaginal flora, as compared with only two patients free of BV with intermediate flora (12%) from among the 16 placebo-treated women (p <0.001). Two weeks after completion of therapy, treatment was successful (score <7) in 61% of Lactobacillus-treated patients as compared with 19% of those in the placebo group (p <0.05). In the treatment group, the total number of symptomatic patients and the intensity of their symptoms, in particular vaginal malodour, were significantly reduced at both follow-up visits. The data indicate that intravaginal administration of exogenous selected strains of lactobacilli can restore a normal vaginal microbiota and be used in treating bacterial vaginosis
- …
